Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Clinical trial NCT04342936 · UNKNOWN
Trial details
- NCT number
- NCT04342936
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-17
- Primary completion
- 2023-08-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.